TP53 and B-cell chronic lymphocytic leukemia: However, the majority of cases with heavily pre-treated CLL, TP53 mutations, or clonally related Richter transformation are at high risk of treatment failure, with PFS rates <25% after CHOP-based chemoimmunotherapy (168, 169).